[10-Q] Sintx Technologies, Inc. Quarterly Earnings Report
SINTX Technologies filed its Q3 2025 10‑Q, reporting total revenue of $208k (down 74% year over year) and a net loss of $3.539M. Gross profit was $93k, with operating expenses of $3.448M driven by R&D $1.264M and G&A $2.102M. Cash and cash equivalents were $6.250M as of September 30, 2025.
The company continued shifting away from low‑margin OEM work toward proprietary silicon nitride medical devices. It received FDA 510(k) clearance in October 2025 for the SiNAPTIC Foot & Ankle Osteotomy Wedge System, with revenue expected to begin in the first half of 2026. Q3 also included an inducement in which holders exercised warrants for ~$3.8M in gross proceeds, creating a $6.7M deemed dividend.
SINTX strengthened liquidity with a $6.41M at‑the‑market facility established in October 2025 and expects ~$950k savings from subleasing the armor facility. Management states no significant uncertainty regarding its ability to continue as a going concern through at least November 12, 2026. Shares outstanding were 3,851,956 as of November 7, 2025.
- None.
- None.
Insights
Q3 revenue fell sharply; liquidity bolstered via warrants and ATM.
SINTX posted Q3 revenue of
Financing actions were notable: a warrant inducement generated roughly
The October 510(k) clearance for the foot & ankle wedge system sets up initial sales in 1H
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
OR
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission
File Number
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (IRS Employer | |
| of incorporation or organization) | Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbols | Name of each exchange on which registered | ||
| The
|
Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2)
has been subject to such filing requirements for the past 90 days:
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files);
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
SINTX Technologies, Inc.
Table of Contents
| Part I. Financial Information | |
| Item 1. Financial Statements | |
| Condensed Consolidated Balance Sheets (unaudited) | 3 |
| Condensed Consolidated Statements of Operations (unaudited) | 4 |
| Condensed Consolidated Statements of Stockholders’ Equity (unaudited) | 5 |
| Condensed Consolidated Statements of Cash Flows (unaudited) | 6 |
| Notes to Condensed Consolidated Financial Statements (unaudited) | 7 |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 17 |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 23 |
| Item 4. Controls and Procedures | 23 |
| Part II. Other Information | |
| Item 1. Legal Proceedings | 24 |
| Item 1A. Risk Factors | 24 |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 24 |
| Item 3. Defaults Upon Senior Securities | 24 |
| Item 4. Mine Safety Disclosures | 24 |
| Item 5. Other Information | 24 |
| Item 6. Exhibits | 25 |
| Signatures | 26 |
| 2 |
SINTX Technologies, Inc.
Condensed Consolidated Balance Sheets - Unaudited
(in thousands, except share and per share data)
| September 30, 2025 | December 31, 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Account and other receivables, net of allowance for credit losses of $ | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Inventories | ||||||||
| Total current assets | ||||||||
| Inventories, net | ||||||||
| Property and equipment, net | ||||||||
| Intangible assets, net | ||||||||
| Goodwill | - | |||||||
| Operating lease right of use asset | ||||||||
| Other long-term assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities | ||||||||
| Debt | ||||||||
| Derivative liabilities | ||||||||
| Current portion of operating lease liability | ||||||||
| Other current liabilities | ||||||||
| Total current liabilities | ||||||||
| Operating lease liability, net of current portion | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies | - | - | ||||||
| Stockholders’ equity: | ||||||||
| Convertible preferred stock Series B, $ | - | - | ||||||
| Convertible preferred stock Series C, $ | - | - | ||||||
| Convertible preferred stock Series D, $ | - | - | ||||||
| Convertible preferred stock, value | - | - | ||||||
| Common stock, $ | ||||||||
| Treasury Stock, | ( | ) | - | |||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity | ||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
The condensed consolidated balance sheet as of December 31, 2024, has been prepared using information from the audited consolidated balance sheet as of that date.
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 3 |
SINTX Technologies, Inc.
Condensed Consolidated Statements of Operations - Unaudited
(in thousands, except share and per share data)
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Product revenue | $ | $ | $ | $ | ||||||||||||
| Grant and contract revenue | ||||||||||||||||
| Total revenue | ||||||||||||||||
| Costs of revenue | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Sales and marketing | ||||||||||||||||
| Armor exit costs | - | - | ||||||||||||||
| Reduction in force | - | - | ||||||||||||||
| Grant and contract expenses | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expenses): | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest income | ||||||||||||||||
| Gain (loss) on disposal of equipment | - | ( | ) | ( | ) | |||||||||||
| Change in fair value of derivative liabilities | ( | ) | ( | ) | ||||||||||||
| Offering costs of derivative liabilities | - | - | - | ( | ) | |||||||||||
| Other income, net | - | |||||||||||||||
| Total other income, net | ( | ) | ||||||||||||||
| Net loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Deemed dividend related to warrant inducement | ( | ) | - | ( | ) | - | ||||||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per share – basic and diluted | ||||||||||||||||
| Basic – net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Basic – deemed dividend related to warrant inducement | ( | ) | - | ( | ) | - | ||||||||||
| Basic – attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Diluted – net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Diluted – deemed dividend related to warrant inducement | ( | ) | - | ( | ) | - | ||||||||||
| Diluted – attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | ||||||||||||||||
| Diluted | ||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 4 |
SINTX Technologies, Inc.
Condensed Consolidated Statements of Stockholders’ Equity - Unaudited
(in thousands, except share and per share data)
| Shares | Amount | Shares | Amount | Stock | Capital | Deficit | Equity | |||||||||||||||||||||||||
| Preferred Stock | Common Stock | Treasury | Paid-In | Accumulated | Total | |||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Stock | Capital | Deficit | Equity | |||||||||||||||||||||||||
| Balance as of December 31, 2023 | $ | - | $ | - | $ | - | $ | $ | ( | ) | $ | |||||||||||||||||||||
| Stock based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Common stock issued for cash, net of fees | - | - | - | - | ||||||||||||||||||||||||||||
| Prefunded warrants issued for cash, net of cash fees | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Issuance of common stock from the exercise of prefunded warrants for cash | - | - | - | ( | ) | - | - | |||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance as of March 31, 2024 | - | - | ( | ) | ||||||||||||||||||||||||||||
| Stock based compensation | - | - | - | - | - | |||||||||||||||||||||||||||
| Common stock issued for cash, net of fees | - | - | - | - | ||||||||||||||||||||||||||||
| Extinguishment of derivative liabilities upon exercise of warrants | - | - | - | - | - | |||||||||||||||||||||||||||
| Issuance of common stock from the conversion of preferred stock | ( | ) | - | - | - | - | - | - | ||||||||||||||||||||||||
| Round up of shares issued in reverse stock split | - | - | - | - | - | - | - | |||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance as of June 30, 2024 | - | - | ( | ) | ||||||||||||||||||||||||||||
| Stock based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Common stock issued for cash, net of cash fees | - | - | - | - | ||||||||||||||||||||||||||||
| Issuance of common stock from the conversion of preferred stock | - | ( | ) | - | - | - | - | - | ||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance of as September 30, 2024 | $ | - | $ | $ | - | $ | $ | ( | ) | $ | ||||||||||||||||||||||
| Preferred Stock | Common Stock | Treasury | Paid-In | Accumulated | Total | |||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Stock | Capital | Deficit | Equity | |||||||||||||||||||||||||
| Balance as of December 31, 2024 | $ | - | $ | $ | - | $ | $ | ( | ) | $ | ||||||||||||||||||||||
| Stock based compensation | - | - | - | - | - | |||||||||||||||||||||||||||
| Common stock and prefunded warrants issued for cash, net of fees | - | - | - | - | ||||||||||||||||||||||||||||
| Issuance of common stock from the cashless exercise of warrants | - | - | - | - | - | - | - | |||||||||||||||||||||||||
| Purchase of common stock into Treasury | - | - | - | - | ( | ) | - | - | ( | ) | ||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance as of March 31, 2025 | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Stock based compensation | - | - | - | - | ||||||||||||||||||||||||||||
| Common stock and prefunded warrants issued for cash, net of fees | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||
| Issuance of common stock from the cashless exercise of warrants | - | - | - | - | - | - | - | |||||||||||||||||||||||||
| Purchase of common stock into Treasury | - | - | - | - | ( | ) | - | - | ( | ) | ||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance as of June 30, 2025 | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Balance | $ | - | $ | $ | ( | ) | $ | $ | ( | ) | $ | |||||||||||||||||||||
| Stock based compensation | - | - | - | - | - | |||||||||||||||||||||||||||
| Issuance of common stock for business acquisition | - | - | - | - | ||||||||||||||||||||||||||||
| Issuance of common stock from the cashless exercise of warrants | - | - | - | ( | ) | - | - | |||||||||||||||||||||||||
| Common stock and warrants issued for cash, net of fees | - | - | - | - | ||||||||||||||||||||||||||||
| Deemed dividend related to warrant inducement | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||
| Warrants issued for warrant inducement | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance as of September 30, 2025 | $ | - | $ | $ | ( | ) | $ | $ | ( | ) | $ | |||||||||||||||||||||
| Balance | $ | - | $ | $ | ( | ) | $ | $ | ( | ) | $ | |||||||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 5 |
SINTX Technologies, Inc.
Condensed Consolidated Statements of Cash Flows - Unaudited
(in thousands)
| 2025 | 2024 | |||||||
| Nine Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation expense | ||||||||
| Impairment of Armor | ||||||||
| Amortization of right of use asset | ||||||||
| Loss on disposal of subsidiary | - | |||||||
| Amortization of intangible assets | ||||||||
| Stock based compensation - Employee | ||||||||
| Stock based compensation - Non-employee | - | |||||||
| Change in fair value of derivative liabilities | ( | ) | ||||||
| Bad debt (recoveries) expense | ( | ) | ||||||
| Loss (gain) on disposal of equipment | ( | ) | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Trade accounts receivable | ( | ) | ||||||
| Prepaid expenses and other current assets | ||||||||
| Inventories | ||||||||
| Accounts payable and accrued liabilities | ( | ) | ||||||
| Other liabilities | ( | ) | ||||||
| Payments on operating lease liability | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities | ||||||||
| Purchase of property and equipment | ( | ) | ( | ) | ||||
| Proceeds from acquisition of Sinaptic Surgical | - | |||||||
| Proceeds from notes receivable, net of imputed interest | - | |||||||
| Proceeds from sale of property and equipment | ||||||||
| Disposal of property and equipment, net of cash received | ( | ) | - | |||||
| Net cash provided by (used in) investing activities | ( | ) | ||||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of warrant derivative liabilities | - | |||||||
| Proceeds from issuance of common stock and prefunded warrants, net of cash fees | ||||||||
| Proceeds from exercise of warrants, net of cash fees, and deposit for stock issuance (in other current liabilities) | - | |||||||
| Purchase of common stock into treasury | ( | ) | - | |||||
| Proceeds from issuance of warrants in connection with exercise of warrants | - | |||||||
| Proceeds from issuance of common stock in connection with exercise of warrants | - | |||||||
| Payments on debt | ( | ) | ( | ) | ||||
| Net cash provided by financing activities | ||||||||
| Net increase in cash and cash equivalents | ||||||||
| Cash and cash equivalents at beginning of period | ||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||
| Noncash investing and financing activities | ||||||||
| Debt issued for prepaid insurance | $ | $ | ||||||
| Deemed dividend related to warrant inducement and issuance of warrants | - | |||||||
| Agent warrant offering cost allocated to equity | - | |||||||
| Right of use asset for amended lease liability – increase | - | |||||||
| Reduction of derivative liability upon exercise of warrants | - | |||||||
| Supplemental cash flow information | ||||||||
| Cash paid for interest | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 6 |
SINTX TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Organization and Summary of Significant Accounting Policies
The condensed consolidated financial statements include the accounts of SINTX Technologies, Inc. (“SINTX”, or the “Company”) and its wholly-owned subsidiaries, SINTX Armor, Inc. (“SINTX Armor”), SINTX Agribiotech, Inc., Sinaptic Surgical, LLC, and Technology Assessment and Transfer, Inc. (TA&T) through February 19, 2025 (see Note 2), which are collectively referred to as “we” or the “Company.” SINTX Technologies is an advanced ceramics company formed in December 1996 that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX provides biomedical solutions for medical devices specializing in silicon nitride (Si₃N₄) for musculoskeletal and antipathogenic applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008.
SINTX Core Business
Biomedical Applications: Since its inception, SINTX has been focused on medical grade silicon nitride. SINTX biomedical products have been shown to be biocompatible, bioactive, antipathogenic, and to have superb bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans since 2008 in the U.S., Europe, South America and Asia. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. More recently, in October 2025, SINTX received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SiNAPTIC® Foot & Ankle Osteotomy Wedge System, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the United States. These next-generation implants blend cutting-edge biomaterials science with surgical precision and are designed to elevate standards in orthopedic procedures. SINTX silicon nitride products can be polished to a smooth and wear-resistant surface for articulating applications, such as bearings for hip and knee replacements.
We believe that silicon nitride has a superb combination of properties that make it suited for long-term human implantation. Other biomaterials are based on bone grafts, metal alloys, and polymers- all of which have well-known practical limitations and disadvantages. In contrast, silicon nitride has a legacy of success in the most demanding and extreme industrial environments. Bacterial infection of any biomaterial implants is always a concern. SINTX silicon nitride has been shown to be resistant to bacterial colonization and biofilm formation, making it antibacterial. As a human implant material, silicon nitride offers bone ingrowth, resistance to bacterial and viral infection, ease of diagnostic imaging, resistance to corrosion, and superior strength and fracture resistance, all of which claims are validated in our large and growing inventory of peer-reviewed, published literature reports. We believe that our versatile silicon nitride manufacturing expertise positions us favorably to introduce new and innovative devices in the medical and non-medical fields.
Antipathogenic Applications: Today, there is a global need to improve protection against pathogens in everyday life. SINTX believes that by incorporating its unique composition of silicon nitride antipathogenic powder into products such as face masks, drapes, filters, sutures, and wound care devices, it is possible to manufacture surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. The discovery in 2020 that SINTX silicon nitride inactivates SARS-CoV-2, the virus which causes the disease COVID-19, has opened new markets and applications for our material. We presently manufacture advanced ceramic powders and components in our manufacturing facilities based in Salt Lake City, Utah.
The SINTX Salt Lake City facility is registered with the FDA, is cGMP and ANVISA RDC 665 compliant, as well as being ISO 9001:2015, ISO 13485:2016 certified, and ASD9100D certified. The Company’s products are primarily sold in the United States.
Basis of Presentation
These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company.
SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 19, 2025. The results of operations for the nine months ended September 30, 2025, are not necessarily indicative of the results to be expected for the year ending December 31, 2025. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2024.
Segment Information
The
Company operates as
Reverse Stock Split
On
May 28, 2024, the Company effected a
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of September 30, 2025, the most significant estimate relates to derivative liabilities relating to common stock warrants.
| 7 |
Reclassification
Certain other prior period balances have been reclassified to conform to the current period presentation.
Liquidity and capital resources
The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, decrease expenses and raise additional funding. We continue to seek opportunities to raise additional funding through equity and/or debt financing. However, such funding is not guaranteed and may not be available to the Company on favorable terms and may involve restrictive covenants. If the Company is not able to obtain additional debt or equity financing, the impact on the Company will be material and adverse.
The board of directors, together with management, remains focused on advancing the Company’s business strategy and focus. We are concentrating our resources on high-growth areas within the healthcare sector where our proprietary materials and technologies—such as silicon nitride—provide a distinct competitive advantage due to their unique strength, durability, and biocompatibility. Through this transformation, as demonstrated by the recent FDA 510(k) clearance of our SiNAPTIC® Foot & Ankle Osteotomy Wedge System, our aim is to deliver meaningful innovations to the medical community. By focusing on partnerships and collaborations with healthcare institutions and industry leaders, SINTX is positioned to expand its footprint in the medical device sector and drive shareholder value through sustainable, high-impact innovations.
On August 8, 2024, the board of directors approved a plan to implement a Company-wide reduction in the workforce. This decision was part of the Company’s ongoing strategic review of its operations aimed at improving operational efficiency and reducing costs.
On August 12, 2024, the board of directors approved a plan to cease efforts to make the armor plant operational. This decision was made to streamline operations and focus on core business areas that align with the Company’s long-term strategic goals. The armor plant had not been fully operational since the acquisition of the armor equipment in July 2021 and had been completely shut down since October 2023.
As discussed in Note 2 to the condensed consolidated financial statements, on February 19, 2025, the Company sold to Tethon all the issued and outstanding shares of TA&T in exchange for the assumption by Tethon of the outstanding liabilities of TA&T.
As discussed in further detail above, in October 2025, the Company received FDA 510(k) clearance for a new foot and ankle osteotomy wedge system, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the United States. Revenue is expected to begin during the first half of 2026.
As
discussed in Note 14 to the condensed consolidated financial statements, in October 2025, the Company entered into the 2025 ATM Agreement
to sell shares of its common stock from time to time, through an “at the market offering” program, having an aggregate offering
price of $
As
discussed in Note 12 to the condensed consolidated financial statements, in October 2025, the Company entered into a sublease agreement
to lease the SINTX armor facility, that is expected to save the Company approximately $
The Company believes that based on its existing capital resources and funds generated by operations, there is no significant uncertainty of the Company’s ability to continue as a going concern through at least November 12, 2026.
Recent Accounting Pronouncements
ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures
In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” on the topic of income taxes. The standard requires additional disclosure for income taxes. These requirements include: (i) requiring a public entity to disclose specific categories in the rate reconciliation; (ii) disclosure of additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5% of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate); (iii) annual disclosure of the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes; (iv) annual disclosure of the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5% of total income taxes paid (net of refunds received); (v) annual disclosure of income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign; and (vi) annual disclosure of income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. For public entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company will adopt this guidance in fiscal 2025 and is in the process of evaluating the new requirements. As a result, the Company has not yet determined the impact this new ASU will have on its disclosures.
ASU 2024-03, Income Statement—Reporting Comprehensive Income (Topic 220): Disaggregation of Income Statement Expenses
In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income (Topic 220): Disaggregation of Income Statement Expenses,” which requires public business entities, such as the Company, to provide disaggregated disclosure of specific natural expense categories underlying certain income statement expense line items in the notes to the financial statements. The standard identifies five required natural expense categories for disaggregation—employee compensation, depreciation, amortization, inventory expense, and other manufacturing expenses—along with a residual “other” category for remaining amounts within relevant expense captions (e.g., cost of sales, selling, general and administrative expenses). ASU 2024-03 does not alter the expense captions presented on the face of the income statement but enhances footnote disclosures to improve transparency. The standard is effective for annual periods beginning after December 15, 2026, with early adoption permitted, and must be applied prospectively, though retrospective application is optional. An update in ASU 2025-01 clarified that interim period disclosures are not required until annual periods beginning after December 15, 2027. The Company is in the process of evaluating the impact of ASU 2024-03 on its consolidated financial statements. We expect adoption to necessitate modifications to our financial reporting processes and systems to capture and disclose the required disaggregated expense information in the footnotes. Management anticipates that this will enhance the granularity of expense disclosures but does not expect a material effect on our reported financial position or results of operations. We are reviewing our current expense classification practices and data collection capabilities to ensure compliance with the new requirements upon adoption.
The Company has determined that recently issued accounting standards, other than the above discussed, will not have a material impact on its consolidated financial position, results of operations or cash flows.
| 8 |
2. Disposition of TA&T
On February 19, 2025, the Company entered into an Entity Acquisition Agreement (the “Agreement”) with Tethon Corporation (“Tethon”), pursuant to which the Company sold to Tethon all the issued and outstanding shares of TA&T in exchange for the assumption by Tethon of the outstanding liabilities of TA&T. The disposal did not represent a strategic shift that will have a major effect on the Company’s operations and financials and, therefore, did not qualify for discontinued operations treatment under ASC 205-20.
The following table summarizes the carrying amounts of the major classes of assets and liabilities of TA&T at the date of sale that were transferred to the Tethon (in thousands):
Schedule of Major Classes of Assets and Liabilities of TA & T at the Date of Sale
| February 19, 2025 | ||||
| Cash and cash equivalents | $ | |||
| Inventories | ||||
| Accounts receivable | ||||
| Right of use asset | ||||
| Property and equipment, net | ||||
| Other assets | ||||
| Total assets sold | ||||
| Accounts payable | ( | ) | ||
| Accrued expenses | ( | ) | ||
| Operating lease liability | ( | ) | ||
| Other liabilities | ( | ) | ||
| Total liabilities assumed | ( | ) | ||
| Net assets sold | $ | |||
No consideration was paid other than the assumption by Tethon of the above liabilities. No significant transaction costs were incurred. No earnout or other contingent consideration arrangements were included in the Agreement.
3. Business Combinations
On
July 1, 2025, the Company entered into an Asset Purchase Agreement with Sinaptic Surgical, LLC (“Sinaptic Surgical”) and
Sinaptic Holdings, LLC (“Holdings”), pursuant to which the Company agreed to purchase substantially all the assets and assume
certain liabilities of Sinaptic Surgical. As consideration for the purchase of the assets under the Asset Purchase Agreement, the Company
agreed to issue to Sinaptic Surgical warrants to purchase
The fair value for the acquired intangible asset was estimated utilizing the income approach, which involves the use of significant estimates and assumptions including projected revenue growth rates, projected earnings, and discount rates.
The following table summarizes the consideration transferred, the estimated fair value of the assets acquired, and liabilities assumed, at the acquisition date (in thousands):
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
| Amounts recognized as of the acquisition date | ||||
| Fair value of consideration transferred | ||||
| Common stock private placement | $ | |||
| Warrants (included in derivative liabilities) | ||||
| Total consideration transferred | $ | |||
| Recognized amounts of identifiable assets acquired and liabilities assumed | ||||
| Cash | $ | |||
| Intangibles | ||||
| Total assets acquired | ||||
| Accounts payable and other accrued expenses | ( | ) | ||
| Total identifiable net assets | $ | |||
| Goodwill | $ | |||
The
Company recognized goodwill of $
| 9 |
4. Basic and Diluted Net Income (Loss) per Common Share
Basic
net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding
for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss
by the weighted-average number of common share equivalents outstanding for the period that are determined to be dilutive. Common stock
equivalents are primarily comprised of preferred stock and warrants for the purchase of common stock. The Company had potentially dilutive
securities of approximately
Below are basic and diluted loss per share data for the three months ended September 30, 2025, which are in thousands except for share and per share data:
Schedule of Basic and Diluted Loss Per Share
| Basic Calculation | Effect of Dilutive | Diluted Calculation | ||||||||||
| Numerator: | ||||||||||||
| Net loss | $ | ( | ) | $ | - | $ | ( | ) | ||||
| Deemed dividend related to warrant inducement | ( | ) | - | ( | ) | |||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | - | $ | ( | ) | ||||
| Denominator: | ||||||||||||
| Number of shares used in per common share calculations: | - | |||||||||||
| Net loss per common share: | ||||||||||||
| Net loss | $ | ( | ) | $ | - | $ | ( | ) | ||||
| Deemed dividend related to warrant inducement | ( | ) | - | ( | ) | |||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | - | $ | ( | ) | ||||
Below are basic and diluted loss per share data for the nine months ended September 30, 2025, which are in thousands except for share and per share data:
| Basic Calculation | Effect of Dilutive | Diluted Calculation | ||||||||||
| Numerator: | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Deemed dividend related to warrant inducement | ( | ) | - | ( | ) | |||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Denominator: | ||||||||||||
| Number of shares used in per common share calculations: | ||||||||||||
| Net loss per common share: | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Deemed dividend related to warrant inducement | ( | ) | - | ( | ) | |||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Below are basic and diluted loss per share data for the three months ended September 30, 2024, which are in thousands except for share and per share data:
| Basic Calculation | Effect of Dilutive | Diluted Calculation | ||||||||||
| Numerator: | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Deemed dividend related to warrant inducement | - | - | - | |||||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Denominator: | ||||||||||||
| Number of shares used in per common share calculations: | ||||||||||||
| Net loss per common share: | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Deemed dividend related to warrant inducement | - | - | - | |||||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| 10 |
Below are basic and diluted loss per share data for the nine months ended September 30, 2024, which are in thousands except for share and per share data:
| Basic Calculation | Effect of Dilutive | Diluted Calculation | ||||||||||
| Numerator: | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Deemed dividend related to warrant inducement | - | - | - | |||||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Denominator: | ||||||||||||
| Number of shares used in per common share calculations: | ||||||||||||
| Net loss per common share: | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Deemed dividend related to warrant inducement | - | - | - | |||||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | (19.59 | ) | |||
5. Inventories
Inventories
consisted of the following (in thousands):
Schedule of Components of Inventory
| September 30, 2025 | December 31, 2024 | |||||||
| Raw materials | $ | $ | ||||||
| WIP | ||||||||
| Finished goods | ||||||||
| Inventory net | $ | $ | ||||||
As
of September 30, 2025, inventories of approximately $
6. Fair Value Measurements
Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis
The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have certain rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:
| Level 1 - | quoted market prices for identical assets or liabilities in active markets. | |
| Level 2 - | observable prices that are based on inputs not quoted on active markets but corroborated by market data. | |
| Level 3 - | unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. |
The
Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant
to their fair value measurement. No financial assets or liabilities (except the derivative liabilities explained above) were measured
on a recurring basis as of September 30, 2025, and December 31, 2024. The following tables set forth the financial liabilities measured
at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2025, and December 31, 2024 (in thousands):
Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy
| Fair Value Measurements as of September 30, 2025 | ||||||||||||||||
| Description | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
| Derivative liabilities: | ||||||||||||||||
| Common stock warrants | $ | - | $ | - | $ | $ | ||||||||||
| Fair Value Measurements as of December 31, 2024 | ||||||||||||||||
| Description | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
| Derivative liabilities: | ||||||||||||||||
| Common stock warrants | $ | - | $ | - | $ | $ | ||||||||||
| 11 |
The
Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during
the nine months ended September 30, 2025, and 2024. The following table presents a reconciliation of the derivative liabilities measured
at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2025, and
2024 (in thousands):
Schedule of Fair Value Measurement Hierarchy of Derivative Liability
| Common Stock Warrants | ||||
| Balance as of December 31, 2023 | $ | |||
| Issuance of derivatives | ||||
| Exercise of warrants | ( | ) | ||
| Change in fair value | ( | ) | ||
| Other | ||||
| Balance as of September 30, 2024 | $ | |||
| Balance as of December 31, 2024 | $ | |||
| Issuance of derivatives | ||||
| Change in fair value | ||||
| Balance as of September 30, 2025 | $ | |||
Common Stock Warrants
The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. As of September 30, 2025, and December 31, 2024, the derivative liability was calculated using the Monte Carlo simulation valuation.
The assumptions used in estimating the common stock warrant liability using the Monte Carlo simulation valuation model as of September 30, 2025, and December 31, 2024 were as follows:
Schedule of Assumptions Used in Estimating Fair Value
| September 30, 2025 | December 31, 2024 | |||||||
| Weighted-average risk-free interest rate | % | % | ||||||
| Weighted-average expected life (in years) | ||||||||
| Expected dividend yield | - | % | - | % | ||||
| Weighted-average expected volatility | % | % | ||||||
Other Financial Instruments
The Company’s recorded values of cash and cash equivalents, account and other receivables, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of notes payable approximates the fair value as the interest rate approximates market interest rates.
7. Accrued and Other Current Liabilities
Accrued liabilities consisted of the following (in thousands):
Schedule of Accrued and Other Current Liabilities
| September 30, 2025 | December 31, 2024 | |||||||
| Payroll and related expense | $ | $ | ||||||
| Accrued payables | ||||||||
| Other | ||||||||
| Accrued other liabilities | $ | $ | ||||||
Other
current liabilities consisted of deposits for stock issuance of $
| 12 |
8. Debt
Insurance Premium Finance Arrangements
In
June 2024, in connection with securing commercial liability insurance, the Company entered into a Premium Finance Arrangement to extend
the premium payment out for a period of 10 months. The Company paid a total of $
In
March 2025, in connection with securing Director and Officer professional liability insurance, the Company entered into a Premium Finance
Arrangement to extend the premium payment out for a period of 10 months. The Company paid a total of $
In
May 2025, in connection with securing general liability insurance, the Company entered into a Premium Finance Arrangement to extend the
premium payment out for a period of 5 months. The Company paid a total of $
9. Equity
2025 Warrant Inducement
On
September 8, 2025, the Company entered into an inducement agreement (the “Inducement Letter”) with certain holders of certain
of the Company’s existing warrants to purchase up to an aggregate of
Pursuant
to the Inducement Letter, the warrant holders agreed to exercise for cash the existing warrants to purchase an aggregate of
The Company estimated the fair value of each warrant on the issuance
date using the Black-Scholes-Merton valuation model. The aggregate fair value of the new warrants issued as part of the inducement was
$
2025 Capital Raise and registration of shares
On
February 20, 2025, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) under which it sold
securities to certain institutional and accredited investors for aggregate gross proceeds of $
2024 April Registered Offering
On
April 5, 2024, the Company closed a public offering of
| 13 |
2024 March Registered Offering
On
March 26, 2024, the Company closed a public offering of
2024 February Registered Offering
On
February 2, 2024, the Company completed a public offering of
2021 Equity Distribution Agreement
On
February 25, 2021, the Company entered into an Equity Distribution Agreement (the “2021 ATM Agreement”) with Maxim Group
LLC (the “Agent”) as sales agent. The agreement permitted the Company to offer and sell shares of its common stock, par value
$
| 14 |
10. Stock-Based Compensation
A summary of the Company’s outstanding stock option activity for the nine months ended September 30, 2025, and 2024 is as follows:
Schedule of Stock Option Activity
| September 30, 2025 | ||||||||||||||||
Weighted- Average | Weighted- Average Remaining Contractual | |||||||||||||||
| Options | Exercise Price | Life (Years) | Intrinsic Value | |||||||||||||
| As of December 31, 2024 | $ | $ | - | |||||||||||||
| Granted | - | |||||||||||||||
| Exercised | - | - | - | - | ||||||||||||
| Forfeited | - | - | - | - | ||||||||||||
| Expired | ( | ) | - | - | ||||||||||||
| As of September 30, 2025 | $ | $ | ||||||||||||||
| Exercisable at September 30, 2025 | $ | $ | ||||||||||||||
| Vested and expected to vest at September 30, 2025 | $ | $ | ||||||||||||||
| September 30, 2024 | ||||||||||||||||
Weighted- Average | Weighted- Average Remaining Contractual | |||||||||||||||
| Options | Exercise Price | Life (Years) | Intrinsic Value | |||||||||||||
| As of December 31, 2023 | $ | $ | - | |||||||||||||
| Granted | - | - | - | - | ||||||||||||
| Exercised | - | - | - | - | ||||||||||||
| Forfeited | ( | ) | - | - | ||||||||||||
| Expired | ( | ) | - | - | ||||||||||||
| As of September 30, 2024 | $ | $ | - | |||||||||||||
| Exercisable at September 30, 2024 | $ | $ | - | |||||||||||||
| Vested and expected to vest at September 30, 2024 | $ | $ | - | |||||||||||||
The Company estimates the fair value of each stock option on the grant date using the Black-Scholes-Merton valuation model, which requires several estimates including an estimate of the fair value of the underlying common stock on grant date. The expected volatility was based on an average of the historical volatility of the Company. The expected term was contractual life of option. The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option.
Of
the
Unrecognized stock-based compensation as of September 30, 2025, is as follows:
Schedule of Unrecognized Stock-based Compensation
| Unrecognized | Weighted Average | |||||||
| Stock-Based Compensation | Remaining of Recognition | |||||||
| (in thousands) | (in years) | |||||||
| Stock options | $ | - | - | |||||
| Stock grants | $ | |||||||
11. Commitments and Contingencies
The Company has executed agreements with certain executive officers of the Company which, upon the occurrence of certain events related to a change in control, call for payments to the executives up to three times their annual salary and accelerated vesting of previously granted stock awards.
From time to time, the Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results or cash flows.
| 15 |
12. Leases
The Company has entered into multiple operating leases from which it conducts its business.
SINTX
The Company leases
SINTX Armor
The
Company, on behalf of SINTX Armor, leases approximately
TA&T
In connection with the disposition of TA&T, the lease facilities, including right of use assets and lease liabilities, were transferred to Tethon (see Note 2).
Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. The Company accounts for lease components separately from the non-lease components. The depreciable life of the assets and leasehold improvements are limited by the expected lease term.
As
of September 30, 2025, operating lease right-of-use assets were approximately $
Operating lease future minimum payments together with the present values as of September 30, 2025, are summarized as follows (in thousands):
Schedule of Operating Lease Future Minimum Payments
| Years Ending December 31, | Amount | |||
| 2025 (Remainder) | $ | |||
| 2026 | ||||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| Thereafter | ||||
| Total future minimum lease payments | ||||
| Less amounts representing interests | ( | ) | ||
| Present value of lease liability | ||||
| Current portion of operating lease liability | ||||
| Long-term portion operating lease liability | $ | |||
13. Related Party Transactions
During
the nine months ended September 30, 2025, the Company entered into a Research Collaboration Agreement (“Research Agreement”)
with a company that is majority owned by a shareholder of the Company. The Company paid $
14. Subsequent Events
Wainwright ATM
On
October 3, 2025, the Company entered into an At The Market Offering Agreement (the “2025 ATM Agreement”) with H.C. Wainwright
& Co., LLC, as sales agent (“Wainwright”), to sell shares of its common stock, par value $
Sublease Agreement
On October 30, 2025,
the Company entered into a Sublease Agreement (the “Sublease”) with Hayes Performance Systems, Inc., a Delaware corporation
(“Hayes”), pursuant to which the Company agreed to sublease to Hayes all of the premises the Company currently leases under
its Industrial Lease Agreement dated August 19, 2021 with SLS Industrial Portfolio Owner SLCP, LLC (the “Prime Lease”). The
| 16 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements for the year ended December 31, 2024 and the notes thereto, along with Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed separately with the U.S. Securities and Exchange Commission. This discussion and analysis contains forward-looking statements based upon current beliefs, plans, expectations, intentions and projections that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2024, and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q and in other filings with the Securities and Exchange Commission we may make from time-to-time.
Overview
SINTX Technologies is an advanced ceramics company formed in December 1996 that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX provides biomedical solutions for medical devices specializing in silicon nitride (Si₃N₄) for musculoskeletal and antipathogenic applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008.
SINTX Core Business
Biomedical Applications: Since its inception, SINTX has been focused on medical grade silicon nitride. SINTX biomedical products have been shown to be biocompatible, bioactive, antipathogenic, and to have superb bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans since 2008 in the U.S., Europe, South America and Asia. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. More recently, in October 2025, SINTX received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SiNAPTIC® Foot & Ankle Osteotomy Wedge System, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the United States. These next-generation implants blend cutting-edge biomaterials science with surgical precision and are designed to elevate standards in orthopedic procedures. SINTX silicon nitride products can be polished to a smooth and wear-resistant surface for articulating applications, such as bearings for hip and knee replacements.
We believe that silicon nitride has a superb combination of properties that make it suited for long-term human implantation. Other biomaterials are based on bone grafts, metal alloys, and polymers- all of which have well-known practical limitations and disadvantages. In contrast, silicon nitride has a legacy of success in the most demanding and extreme industrial environments. Bacterial infection of any biomaterial implants is always a concern. SINTX silicon nitride has been shown to be resistant to bacterial colonization and biofilm formation, making it antibacterial. As a human implant material, silicon nitride offers bone ingrowth, resistance to bacterial and viral infection, ease of diagnostic imaging, resistance to corrosion, and superior strength and fracture resistance, all of which claims are validated in our large and growing inventory of peer-reviewed, published literature reports. We believe that our versatile silicon nitride manufacturing expertise positions us favorably to introduce new and innovative devices in the medical and non-medical fields.
Antipathogenic Applications: Today, there is a global need to improve protection against pathogens in everyday life. SINTX believes that by incorporating its unique composition of silicon nitride antipathogenic powder into products such as face masks, drapes, filters, sutures, and wound care devices, it is possible to manufacture surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. The discovery in 2020 that SINTX silicon nitride inactivates SARS-CoV-2, the virus which causes the disease COVID-19, has opened new markets and applications for our material.
We presently manufacture advanced ceramic powders and components in our manufacturing facilities based in Salt Lake City, Utah.
The SINTX Salt Lake City facility is registered with the FDA, is cGMP and ANVISA RDC 665 compliant, as well as being ISO 9001:2015, ISO 13485:2016 certified, and ASD9100D certified. The Company’s products are primarily sold in the United States.
| 17 |
Components of our Results of Operations
We manage our business within one reportable segment, which is consistent with how our management reviews our business, makes investment and resource allocation decisions, and assesses operating performance.
Revenue
Our product revenue is derived from the manufacture and sale of products. These revenue sources primarily include coatings, materials, and components for aerospace and medical device markets, toll processing services, and government contracts and grants. We generally recognize revenue from sales where control transfers at a point in time as the title and risk of loss passes to the customer, which is at the time the product is shipped. In general, our customer does not have rights of return or exchange.
We believe our product revenue will increase as we complete development and obtain regulatory clearance for our product candidates and secure opportunities to manufacture third party products with silicon nitride.
We also derive grant and contract revenue from awards provided by governmental agencies.
Cost of revenue
The expenses that are included in cost of revenue include all in-house manufacturing costs for the products we manufacture.
Gross profit
Our gross profit measures our product revenue relative to our cost of revenue.
Research and development expenses
Our research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, clinical trials, test-part manufacturing, testing, developing and validating the manufacturing process, manufacturing, facility and regulatory-related costs. Research and development expenses also include employee compensation, employee and non-employee stock-based compensation, supplies and materials, consultant services, and travel and facilities expenses related to research and development activities.
We expect to incur additional research and development costs as we continue to develop new medical devices, related product candidates for antipathogenic applications, and other products which may increase our total research and development expenses.
General and administrative expenses
General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation for certain members of our executive team and board of directors, and other personnel employed in finance, legal, compliance, administrative, information technology, customer service, executive and human resource departments. General and administrative expenses also include other expenses not part of the other cost categories mentioned above, including facility expenses and professional fees for accounting and legal services.
| 18 |
RESULTS OF OPERATIONS
The following is a tabular presentation of our unaudited condensed consolidated operating results for the three and nine months ended September 30, 2025 and 2024 (in thousands):
Three Months Ended | $ | % | Nine Months Ended September 30, | $ | % | |||||||||||||||||||||||||||
| 2025 | 2024 | Change | Change | 2025 | 2024 | Change | Change | |||||||||||||||||||||||||
| Product revenue | $ | 150 | $ | 367 | $ | (217 | ) | -59 | % | $ | 541 | $ | 1,054 | $ | (513 | ) | -49 | % | ||||||||||||||
| Grant and contract revenue | 58 | 432 | (374 | ) | -87 | % | 187 | 1,291 | (1,104 | ) | -86 | % | ||||||||||||||||||||
| Total revenue | 208 | 799 | (591 | ) | -74 | % | 728 | 2,345 | (1,617 | ) | -69 | % | ||||||||||||||||||||
| Cost of revenue | 115 | 210 | (95 | ) | -45 | % | 455 | 657 | (202 | ) | -31 | % | ||||||||||||||||||||
| Gross profit | 93 | 589 | (496 | ) | -84 | % | 273 | 1,688 | (1,415 | ) | -84 | % | ||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||||||||
| Research and development | 1,264 | 796 | 468 | 59 | % | 3,618 | 4,492 | (874 | ) | -19 | % | |||||||||||||||||||||
| General and administrative | 2,102 | 802 | 1,300 | 162 | % | 4,836 | 2,997 | 1,839 | 61 | % | ||||||||||||||||||||||
| Sales and marketing | 59 | 87 | (28 | ) | -32 | % | 100 | 589 | (489 | ) | -83 | % | ||||||||||||||||||||
| Armor exit costs | - | 4,457 | (4,457 | ) | -100 | % | - | 4,457 | (4,457 | ) | -100 | % | ||||||||||||||||||||
| Reduction in force | - | 407 | (407 | ) | -100 | % | - | 407 | (407 | ) | -100 | % | ||||||||||||||||||||
| Grant and contract expenses | 23 | 448 | (425 | ) | -95 | % | 122 | 1,061 | (939 | ) | -89 | % | ||||||||||||||||||||
| Total operating expenses | 3,448 | 6,997 | (3,549 | ) | -51 | % | 8,676 | 14,003 | (5,327 | ) | -38 | % | ||||||||||||||||||||
| Loss from operations | (3,355 | ) | (6,408 | ) | 3,053 | -48 | % | (8,403 | ) | (12,315 | ) | 3,912 | -32 | % | ||||||||||||||||||
| Other income (expense) | (184 | ) | 169 | (353 | ) | -209 | % | 254 | 2,986 | (2,732 | ) | -91 | % | |||||||||||||||||||
| Net loss before taxes | (3,539 | ) | (6,239 | ) | 2,700 | -43 | % | (8,149 | ) | (9,329 | ) | 1,180 | -13 | % | ||||||||||||||||||
| Provision for income taxes | - | - | - | - | % | - | - | - | - | % | ||||||||||||||||||||||
| Net loss | $ | (3,539 | ) | $ | (6,239 | ) | $ | 2,700 | -43 | % | $ | (8,149 | ) | $ | (9,329 | ) | $ | 1,180 | -13 | % | ||||||||||||
Revenue
For the three months ended September 30, 2025, product revenue decreased $0.2 million, or 59%, compared to the same period in 2024. During the three months ended September 30, 2025, grant and contract revenue decreased $0.4 million, or 87% as compared to the same period in 2024.
For the nine months ended September 30, 2025, product revenue decreased $0.5 million, or 49%, compared to the same period in 2024. During the nine months ended September 30, 2025, grant and contract revenue decreased $1.1 million, or 86% as compared to the same period in 2024.
Revenue trends and strategic focus
The decrease in total revenue for the two periods was primarily due to the Company’s ongoing strategic repositioning away from non-core, low-margin OEM technical manufacturing contracts that did not support long-term profitability. This planned reduction in OEM-related revenue is consistent with our corporate shift toward commercializing proprietary silicon nitride-based biomedical devices, which we believe offer stronger margins, a more defensible competitive position, and better long-term value for shareholders.
While this strategic realignment has led to a decline in reported revenue, we believe it is a necessary step in positioning the Company for sustainable growth. During this transitional period, we continue to invest in the development and regulatory advancement of silicon nitride-based orthopedic and surgical implants, as evidenced by the recently received 510(k) clearance for osteotomy wedges used in foot and ankle fusion procedures. Additionally, we entered into a private label agreement to supply OsseoSculpt™, a next next-generation biologic designed to complement the foot and ankle osteotomy wedges. We began recognizing commercial revenue from OsseoSculpt™ in Q3 2025. We believe that these products will serve as key revenue drivers beginning in 2026.
Cost of revenue and Gross profit
For the three months ended September 30, 2025, cost of revenue decreased $0.1 million, or 45%, compared to the same period in 2024 primarily due to the decrease in revenue mentioned above.
For the nine months ended September 30, 2025, cost of revenue decreased $0.2 million, or 31%, compared to the same period in 2024 primarily due to the decrease in revenue mentioned above.
Research and development expenses
For the three months ended September 30, 2025, research and development expenses increased $0.5 million, or 59%, compared to the same period in 2024, primarily due to an increase in costs related to the Research Agreement (see Note 13).
For the nine months ended September 30, 2025, research and development expenses decreased $0.9 million, or 19%, compared to the same period in 2024, primarily due to a decrease in payroll related costs, patent expenses, prototypes, and outside consulting costs, partially offset by an increase in costs related to the Research Agreement (see Note 13).
General and administrative expenses
For the three months ended September 30, 2025, general and administrative expenses increased $1.3 million, or 162%, compared to the same period in 2024, primarily due to increased stock-based compensation and other headcount related costs, partially offset by lower legal expenses and outside consulting costs.
For the nine months ended September 30, 2025, general and administrative expenses increased $1.8 million, or 61%, compared to the same period in 2024, primarily due to increased stock-based compensation and other headcount related costs, and fees paid to departing members of the board of directors, partially offset by lower legal expenses and outside consulting costs.
| 19 |
Sales and marketing expenses
For the three months ended September 30, 2025, sales and marketing expenses remained consistent compared to the same period in 2024.
For the nine months ended September 30, 2025, sales and marketing expenses decreased $0.5 million, or 83%, compared to the same period in 2024, primarily due to an overall decrease in payroll related costs.
Armor Exit Costs
For the three and nine months ended September 30, 2025, Armor exit costs decreased $4.5 million, or 100%, as compared to the same period in 2024 due to asset impairment costs at the SINTX Armor facility.
Reduction in Force Expenses
For the three and nine months ended September 30, 2025, reduction in force expenses decreased $0.4 million, or 100%, as compared to the same period in 2024 due to payroll expenses related to severance and accrued vacation payouts.
Grant and contract expenses
For the three months ended September 30, 2025, grant and contract expenses decreased $0.4 million, or 95%, compared to the same period in 2024, primarily due to the decrease in grant and contract revenue associated with the sale of the TA&T subsidiary.
For the nine months ended September 30, 2025, grant and contract expenses decreased $0.9 million, or 89%, compared to the same period in 2024, primarily due to the decrease in grant and contract revenue associated with the sale of the TA&T subsidiary.
Other income, net
For the three months ended September 30, 2025, other income decreased $0.4 million, or 209%, compared to the same period in 2024, primarily due to a $0.4 million decrease in the change in value of derivative liabilities.
For the nine months ended September 30, 2025, other income decreased $2.7 million, or 91%, compared to the same period in 2024, primarily due to a $3.1 million decrease in the change in value of derivative liabilities, partially offset by a $0.3 million gain on disposal of property and equipment associated with SINTX Armor, and a $0.1 million increase in interest income.
Liquidity and capital resources
The condensed consolidated financial statements have been prepared assuming we will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to our ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.
For the nine months ended September 30, 2025, and 2024, we incurred a net loss of $8.1 million and $9.3 million, respectively, and used cash in operating activities of $6.2 million and $7.5 million, respectively. We had an accumulated deficit of $290 million and $282 million as of September 30, 2025, and December 31, 2024, respectively. We will require substantial future capital in order to continue operating our business, conduct research and development and regulatory clearance and approval activities necessary to bring our products to market, and to establish effective marketing and sales capabilities. Our existing capital resources may not be sufficient to enable us to fund the completion of the development and commercialization of all our product candidates.
To date, our operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. We expect that we will continue to generate operating losses and use cash in operations. Our continuation as a going concern is dependent upon its ability to increase sales, decrease expenses and raise additional funding. It is uncertain when, if ever, we will attain profitability and positive cash flows from operations or obtain additional financing.
We continue to seek opportunities to raise additional funding through equity and/or debt financing. However, such funding is not guaranteed and may not be available on favorable terms and may involve restrictive covenants. Any additional equity financing, if available, will most likely be dilutive to its current stockholders. If we are not able to obtain additional debt or equity financing, the impact on our company and business will be material and adverse.
The board of directors, together with management, remains focused on advancing our business strategy and focus. Our strategic emphasis is focused on utilizing our technology in making advancements in the biomedical sector. Historically engaged in both industrial and biomedical applications, we have prioritized the development and commercialization of innovative medical devices, leveraging its expertise in advanced ceramics and biomaterials. This renewed focus aligns with a commitment to improving patient outcomes through the creation of products designed for surgical, orthopedic, and other specialized medical applications. We are concentrating our resources on high-growth areas within the healthcare sector where our proprietary materials and technologies—such as silicon nitride—provide a distinct competitive advantage due to their unique strength, durability, and biocompatibility.
| 20 |
Through this transformation, as demonstrated by the recent FDA 510(k) clearance of our SiNAPTIC® Foot & Ankle Osteotomy Wedge System, our aim is to deliver meaningful innovations to the medical community. Our current research and development pipeline is centered on medical-grade devices that incorporate antimicrobial properties, enhanced imaging capabilities, and durability under physiological conditions, which are critical for orthopedic implants, spinal fusion devices, and other surgical tools. As we transition our focus away from industrial applications, we anticipate this strategic shift will enable us to better serve the medical sector, address critical unmet needs, and position SINTX as a leading provider in the medical device market. By focusing on partnerships and collaborations with healthcare institutions and industry leaders, we believe that we are positioned to expand our footprint in the medical device sector and drive shareholder value through sustainable, high-impact innovations.
On August 8, 2024, the board of directors approved a plan to implement a Company-wide reduction in the workforce. This decision was part of an ongoing strategic review of our operations aimed at improving operational efficiency and reducing costs.
On August 12, 2024, the board of directors approved a plan to cease efforts to make the armor plant operational. This decision was made to streamline operations and focus on core business areas that align with our long-term strategic goals. The armor plant had not been fully operational since the acquisition of the armor equipment in July 2021 and had been completely shut down since October 2023 due to the malfunctioning of the sintering furnace. In connection with this decision, we incurred an impairment charge of approximately $4.6 million during the year ended December 31, 2024. This charge primarily relates to the write-down of certain long-lived assets associated with the armor plant to their estimated fair value.
As discussed in Note 2 to the condensed consolidated financial statements, on February 19, 2025, we entered into an Entity Acquisition Agreement (the “Agreement”) with Tethon Corporation (“Tethon”), pursuant to which the Company sold to Tethon all of the issued and outstanding shares of TA&T in exchange for the assumption by Tethon of the outstanding liabilities of TA&T.
As discussed in Note 1 to the condensed consolidated financial statements, in October 2025, we received FDA 510(k) clearance for a new foot and ankle osteotomy wedge system, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the United States. Revenue is expected to begin during the first half of 2026.
As discussed in Note 14 to the condensed consolidated financial statements, in October 2025, we entered into the 2025 ATM Agreement to sell shares of its common stock from time to time, through an “at the market offering” program, having an aggregate offering price of $6,413,876 was filed with the SEC.
As discussed in Note 12 to the condensed consolidated financial statements, in October 2025, we entered into a sublease agreement to lease the SINTX armor facility, that is expected to save the Company approximately $950,000 over the sublease term.
We believe that based on our existing capital resources and funds generated by our operations, there is no significant uncertainty of the Company’s ability to continue as a going concern through at least November 12, 2026.
Cash Flows
The following table summarizes, for the periods indicated, cash flows from operating, investing and financing activities (in thousands) – unaudited:
| Nine Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Net cash used in operating activities | $ | (6,227 | ) | $ | (7,518 | ) | ||
| Net cash provided by (used in) investing activities | 955 | (204 | ) | |||||
| Net cash provided by financing activities | 7,924 | 9,196 | ||||||
| Net increase in cash | $ | 2,652 | $ | 1,474 | ||||
| 21 |
Net cash used in operating activities
Net cash used in operating activities was $6.2 million during the nine months ended September 30, 2025, compared to $7.5 million used during the nine months ended September 30, 2024, a decrease of $1.3 million. Decrease in net loss of $1.2 million, combined with an increase in accounts payables and other liabilities of $1.0 million, contributed positively to our net cash used in operating activities, partially offset by a decrease in adjustments of non-cash items of $0.5 million, and increases in accounts receivable of $0.4 million.
Net cash provided by (used in) investing activities
Net cash provided by investing activities was $1.0 million during the nine months ended September 30, 2025, compared to net cash used in investing activities of $0.2 million during the nine months ended September 30, 2024, an increase of $1.2 million. The increase in cash provided by investing activities during 2025 was primarily due to $0.8 million in proceeds from the acquisition of Sinaptic Surgical (see Note 3), $0.4 million decrease in purchase of property and equipment and $0.3 million increase in proceeds from the sale of property and equipment, partially offset by a $0.3 million decrease in proceeds from notes receivable.
Net cash provided by financing activities
Net cash provided by financing activities was $7.9 million during the nine months ended September 30, 2025, compared to $9.2 million provided during the same period in 2024. The $1.3 million decrease to net cash provided by financing activities was primarily attributable to a decrease in proceeds from issuance of warrant derivative liabilities of $3.4 million, decrease in proceeds from issuance of common stock and prefunded warrants of $1.7 million, and repurchases of common stock into treasury of $0.1 million, partially offset by increases in proceeds from the exercise of warrants, net of cash fees, and deposit for stock issuance (in other current liabilities) of $3.6 million, and proceeds from issuance of warrants in connection with exercise of warrants of $0.2 million.
Indebtedness
Information with respect to Indebtedness may be found in Note 8 to the condensed consolidated financial statements included in Item 1 of Part I of this report.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements, as defined in Item 303(a)(4) of Regulation S-K.
| 22 |
Critical Accounting Policies and Estimates
A summary of our significant accounting policies and estimates is discussed in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in Note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes to those policies for the nine months ended September 30, 2025.
Recent Accounting Pronouncements
Information with respect to Recent Accounting Pronouncements may be found in Note 1 to the condensed consolidated financial statements included in Item 1 of Part I of this report.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
ITEM 4. CONTROLS AND PROCEDURES
This Report includes the certifications of our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial and Accounting Officer) required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified by the Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act are properly recorded, processed, summarized and reported within the time periods required by the Commission’s rules and forms.
We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial and Accounting Officer), of the effectiveness of the design and operation of these disclosure controls and procedures, as such term is defined in Exchange Act Rule 13a-15(e), as of September 30, 2025. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2025, the end of the period covered by this Quarterly Report on Form 10-Q.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the third quarter of 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 23 |
PART II
ITEM 1. LEGAL PROCEEDINGS
We are not aware of any pending or threatened legal proceeding against us that could have a material adverse effect on our business, operating results or financial condition. The medical device industry is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights as well as improper hiring practices. As a result, we may be involved in various legal proceedings from time to time.
Item 1A. Risk Factors
Information regarding risk factors appears in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 19, 2025. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Share Repurchase Program
In November 2024, the Company announced that its board of directors authorized a share repurchase program that would allow the Company to repurchase up to $500,000 of the Company’s outstanding common stock. The extent to which the Company repurchases its shares, and the timing of such repurchases, will depend upon a variety of factors, including trading volume, market conditions, legal requirements, business conditions and other factors. The repurchase program may be discontinued at any time, and the program does not obligate the Company to acquire any specific number of shares of its common stock. There were no repurchases of shares under the share repurchase program during the third quarter 2025. As of September 30, 2025, the maximum dollar value of shares that may yet be purchased under the program was $366,935.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
None.
| 24 |
ITEM 6. EXHIBITS
| Exhibit Number |
Exhibit Description | Filed Herewith |
Incorporated by Reference herein from Form or Schedule |
Filing Date |
SEC File/ Reg. | |||||
| 4.1 | Form of Warrant | Exhibit 4.1, Form 8-K | 06/27/25 | 001-33624 | ||||||
| 10.1 | Form of Inducement Letter | Exhibit 10.1, Form 8-K | 09/09/25 | 001-33624 | ||||||
| 10.2 | Form of New Warrant | Exhibit 10.2, Form 8-K | 09/09/25 | 001-33624 | ||||||
| 10.3 | Form of Placement Agent Warrant | Exhibit 10.3, Form 8-K | 09/09/25 | 001-33624 | ||||||
| 10.4 | Form of Additional Placement Agent Warrant | Exhibit 10.4, Form 8-K | 09/09/25 | 001-33624 | ||||||
| 10.5 | SINTX Technologies, Inc. 2025 Equity Incentive Plan | Exhibit 10.1, Form S-8 | 09/30/25 | 333-290629 | ||||||
| 10.6 | At The Market Offering Agreement, dated October 3, 2025, by and between the Company and H.C. Wainwright & Co., LLC | Exhibit 10.1, Form 8-K | 10/03/25 | 001-33624 | ||||||
| 31.1 | Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||||||
| 31.2 | Certificate of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||||||
| 32.1 | Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||||||
| 32.2 | Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||||||
| 101.INS | Inline XBRL Instance Document | X | ||||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | ||||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | ||||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | ||||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | X |
| 25 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SINTX Technologies, Inc. | ||
| Date: | November 12, 2025 | /s/ Kevin Trask |
| Kevin Trask | ||
Chief Financial Officer | ||
| (Principal Financial Officer) | ||
| 26 |
FAQ
What were SINT (SINTX Technologies) Q3 2025 revenues and net loss?
Q3 2025 revenue was $208k, and net loss was $3.539M.
How did operating expenses change in Q3 2025 for SINT?
Total operating expenses were $3.448M, including R&D $1.264M and G&A $2.102M.
What was SINTX’s cash position at September 30, 2025?
Cash and cash equivalents were $6.250M.
Did SINTX complete any financing actions in 2025?
Yes. A February private placement raised $5.0M, and a September warrant inducement brought ~$3.8M in gross proceeds with a $6.7M deemed dividend.
What new capital access did SINTX add after quarter‑end?
In October 2025, SINTX entered a new ATM program for up to $6,413,876.
What regulatory milestone did SINTX achieve in October 2025?
The company received FDA 510(k) clearance for the SiNAPTIC Foot & Ankle Osteotomy Wedge System, with revenue expected in the first half of 2026.
How many SINT shares were outstanding recently?
3,851,956 common shares were outstanding as of November 7, 2025.
